ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer

SAN DIEGO, Dec. 27 -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced the initiation of a Phase II clinical trial using CoFactor(R) in the treatment of refractory metastaticterm breast cancer. CoFactor (ANX-510) is a folate-based biomodulator drug designed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-fluorouraciltermtermtermterm (5-FUterm). This study builds on the results of earlier studies and will more fully investigate the efficacy and safety of CoFactor for patients with previously treated, advanced breast cancer. "The initiation of this Phase II clinical trial for CoFactor represents an important milestone in the global registration strategy for our lead product development program," said Evan M. Levine, chief executive officer of ADVENTRX. "We are enthusiastic about CoFactor's potential to enhance the efficacy and safety of 5-FU chemotherapyterm in the treatment of refractory breast cancer."